-640x359.webp&w=1200&q=75)
Melbourne-based 4DMedical (ASX:4DX) announced the deployment of its CT:VQ technology at the Mayo Clinic, consistently ranked as the top hospital in the United States.
The partnership marks the sixth major US Academic Medical Center to adopt the platform, joining the ranks of Stanford, Cleveland Clinic, and the University of Miami.
The integration allows Mayo Clinic's clinical teams to utilise the advanced ventilation and perfusion analysis to enhance diagnostic outputs across various clinical use cases.
The rapid adoption of CT:VQ is a testament to its clinical utility and "extraordinary commercial momentum."
Since receiving FDA clearance in September 2025, 4DMedical has secured these six elite deployments in just seven months.
The technology is revolutionising lung imaging by eliminating the need for radioisotopes and contrast administration, which are standard in traditional nuclear medicine.
By providing superior image resolution and seamlessly integrating into existing CT imaging workflows, the platform offers a more efficient and patient-friendly alternative for assessing lung function.
Industry analysts view the Mayo Clinic endorsement as a "powerful signal" to the broader US healthcare market.
Mayo's adoption validates the transformative potential of 4DMedical’s software-driven approach.